CN1659180B - 新型的重组抗凝血蛋白 - Google Patents

新型的重组抗凝血蛋白 Download PDF

Info

Publication number
CN1659180B
CN1659180B CN03812999XA CN03812999A CN1659180B CN 1659180 B CN1659180 B CN 1659180B CN 03812999X A CN03812999X A CN 03812999XA CN 03812999 A CN03812999 A CN 03812999A CN 1659180 B CN1659180 B CN 1659180B
Authority
CN
China
Prior art keywords
anv
seq
leu
glu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN03812999XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1659180A (zh
Inventor
温子坚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1659180A publication Critical patent/CN1659180A/zh
Application granted granted Critical
Publication of CN1659180B publication Critical patent/CN1659180B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN03812999XA 2002-06-06 2003-06-04 新型的重组抗凝血蛋白 Expired - Fee Related CN1659180B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38693202P 2002-06-06 2002-06-06
US60/386,932 2002-06-06
PCT/US2003/017442 WO2003103577A2 (en) 2002-06-06 2003-06-04 Novel recombinant anticoagulant proteins

Publications (2)

Publication Number Publication Date
CN1659180A CN1659180A (zh) 2005-08-24
CN1659180B true CN1659180B (zh) 2010-06-02

Family

ID=29736237

Family Applications (1)

Application Number Title Priority Date Filing Date
CN03812999XA Expired - Fee Related CN1659180B (zh) 2002-06-06 2003-06-04 新型的重组抗凝血蛋白

Country Status (8)

Country Link
US (2) US7378393B2 (enExample)
EP (1) EP1509541B1 (enExample)
JP (1) JP4444821B2 (enExample)
CN (1) CN1659180B (enExample)
AT (1) ATE534658T1 (enExample)
AU (1) AU2003237351B2 (enExample)
CA (1) CA2486362A1 (enExample)
WO (1) WO2003103577A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7671013B2 (en) * 2003-04-03 2010-03-02 Canadian Blood Services, Inc. Coagulation proteins, coagulation-anticoagulation protein complexes, derivatives thereof and their uses
CA2559167A1 (en) * 2004-03-11 2005-09-22 Alavita, Inc. Modified annexin proteins and methods for preventing thrombosis
US7511016B2 (en) * 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
EP2234631B1 (en) 2007-12-18 2012-09-12 Athera Biotechnologies AB Compounds and methods for the treatment of vascular disease
TR201909412T4 (tr) * 2008-02-22 2019-07-22 Annexin Pharmaceuticals Ab Restenozun önlenmesi veya tedavisi için bileşikler ve yöntemler.
JP5590621B2 (ja) 2008-10-17 2014-09-17 ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド 炎症性障害の処置を処置するためのアネキシンおよびその使用
JP6200806B2 (ja) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
US10040840B2 (en) 2015-10-02 2018-08-07 Silver Creek Pharmaceuticals, Inc. Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
CN113956339B (zh) * 2021-10-28 2023-02-24 中国药科大学 宽体金线蛭抗凝血因子XIa多肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007676A1 (fr) 1987-03-27 1988-10-06 Terumo Kabushiki Kaisha Capteur enzymatique
WO1998029453A1 (en) 1996-12-27 1998-07-09 Mochida Pharmaceutical Co., Ltd. Cell membrane-directed drugs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DENNIS ET AL..Kunitz domain inhibitors of tissue factor-factor VIIa.J. BIOL. CHEM.269 35.1994,269(35),22129 - 22136. *
DENNIS ET AL..Kunitz domain inhibitors of tissue factor-factor VIIa.J. BIOL. CHEM.269 35.1994,269(35),22129- 22136. *
JANG ET AL..Influence of blockade at specific levels of the coagulationcascade on restenosis in a rabbit atherosclerotic femoralartery injury model.CIRCULATION92.1995,923041- 3050. *
LEFKOVITS ET AL..Selective inhibition of factor Xa is more efficient than favtorVII tissue factor complex blockade at facilitating coronarythrombolysis in the canine model.J. AM. COLL. CARDIOL.28 7.1996,28(7),1858 - 1865. *
LEFKOVITS ET AL..Selective inhibition of factor Xa is more efficient than favtorVII tissue factor complex blockade at facilitating coronarythrombolysis in the canine model.J. AM. COLL. CARDIOL.28 7.1996,28(7),1858- 1865. *

Also Published As

Publication number Publication date
US7378393B2 (en) 2008-05-27
EP1509541A2 (en) 2005-03-02
JP4444821B2 (ja) 2010-03-31
AU2003237351A2 (en) 2003-12-22
WO2003103577A2 (en) 2003-12-18
CN1659180A (zh) 2005-08-24
CA2486362A1 (en) 2003-12-18
AU2003237351A1 (en) 2003-12-22
US20050164926A1 (en) 2005-07-28
AU2003237351B2 (en) 2009-12-03
US20090029444A1 (en) 2009-01-29
EP1509541A4 (en) 2006-06-07
JP2005528124A (ja) 2005-09-22
ATE534658T1 (de) 2011-12-15
EP1509541B1 (en) 2011-11-23
WO2003103577A3 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
US20090029444A1 (en) Novel recombinant anticoagulant proteins
US5409895A (en) Protease inhibitory polypeptides derived from urinary trypsin inhibitor and compositions thereof
JP4177457B2 (ja) 膜結合剤と可溶性ペプヂド性化合物の結合体
Wesselschmidt et al. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa
AU749279B2 (en) Modified vitamin K-dependent polypeptides
JP3811186B2 (ja) 線虫から抽出されるセリンプロテアーゼ阻害剤および抗凝固性タンパク質
US6962801B2 (en) Protein for blocking platelet adhesion
EP1135413A2 (en) Proteins that bind angiogenesis-inhibiting proteins, compoisitions and methods of use thereof
JP2000509993A (ja) アポリポタンパク質ｂ―１００由来の抗凝血性ペプチド断片
WO2007101602A9 (en) Chimeric kunitz domains and their use
CA2082226A1 (en) Polypeptide, dna fragment encoding the same, drug composition containing the same and process for producing the same
WO1990015072A1 (en) Platelet aggregation inhibitors and related molecules
US6489451B1 (en) Antithrombosis enzyme from the snake venom of agkistrodon acutus
EP0979276B1 (en) Complement receptor type 1 (cr1)-like sequences
US20020142372A1 (en) Fragments of cr1 and their use
JP2002515245A (ja) プロテインｚ依存性プロテアーゼインヒビター
Côté Studies of structure-function relationships in two human coagulation proteins: factor XII and prothrombin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100602

Termination date: 20200604

CF01 Termination of patent right due to non-payment of annual fee